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2. Abstract 
Introduction: MBL is a serum protein that activates de complement and mediates 
phagocytosis. MBL levels and MBL2 genotypes may impact upon host susceptibility to 
TB or SLE, but evidence to date has been conflicting. No studies have been reported 
analyzing MASP2 polymorphisms and MASP-2 levels in TB and only one in SLE.  
Methods: MBL2 exon 1 and promoter genotyping and serum MBL 
concentrations were determined in a cohort of TB patients (79) an HHC (120) and in a 
cohort of SLE cases (39) and healthy controls (59). Moreover MASP-2 serum levels 
and 5 polymorphisms in the MASP2 gene (Thr73Met, Arg84Gln, Arg103Cys, 
Asp105Gly, Pro111Leuc) were analyzed in 49 TB patients and 50 HHC and in the same 
SLE cohort and healthy controls as before. Most of the participants were Caucasians.  
Results: Diplotype LXPA/HYPA producer of high levels of MBL was 
significantly more frequent in HHC than in patients (16.8% vs 6.4%, p=0.03). 
Significantly higher serum MBL levels were found in patients with active TB than in 
HHC (median MBL concentrations 3420ng/mL [10-28415] and 2600 ng/mL [5-20000] 
respectively, p=0.02). This higher MBL levels were mostly related to the most prevalent 
YA/YA wild-type diplotype.  
In the SLE study LYQC/HYPD, LXPA/LYQC and LYPB/HYPD were only found 
in the SLE patients, and all of them related to severe MBL deficiency (<100ng/mL). 
SLE patients showed a trend to more severe MBL deficiency compared to the control 
group (25.6% and 13.6% respectively, p=0.19). There was a strong correlation between 
MBL2 Exon 1 and promoter genotype and MBL levels in the overall participants. 
Asp105Gly MASP2 variant was the only one detected in the TB and in the SLE study. 
No relation was found between the presence of the allelic variant and the development 
of TB or SLE. No differences were observed in MASP-2 levels or moderate or severe 
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MASP-2 deficiency among TB patients and HHC. There was a tendency towards a 
higher frequency of severe MASP-2 deficiency in SLE patients compared to the control 
group (2/0).  
Conclusions: the high MBL-producer diplotype LXPA/HYPA was significantly 
more frequent in HHC than in TB patients suggesting a protective role against the 
development of TB disease, which was not previously described. SLE patients had a 
trend towards more severe MBL deficiency than healthy controls and some of the low-
MBL producer genotypes were only found in SLE patients suggesting that low MBL 
levels and MBL2 variants could be a risk factor for the development of SLE. 
Asp105Gly MASP2 variant was the only one detected among all the participants. 
Further studies are needed to understand the role of MBL and MASP in TB and SLE 
susceptibility. 
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3. Summary in Spanish 
Introducción: MBL es una proteína sérica que activa el complemento y participa 
en la fagocitosis. Los niveles de MBL y los genotipos de MBL2 podrían interferir, 
dependiendo de la susceptibilidad del huesped, en el desarrollo de tuberculosis o lupus 
eritematoso sistémico, aunque los resultados son controvertidos. Aún no hay estudios 
publicados que analicen la relación entre los polimorfismos de MASP2 y los niveles de 
MASP-2 con tuberculosis y únicamente uno con lupus eritematoso sistémico. 
Métodos: se determinaron los genotipos del exon 1 y del promotor del MBL2 y 
las concentraciones de MBL en una cohorte de pacientes con tuberculosis (79) y en 
contactos sanos (120), así como en una cohorte de pacientes con lupus (39) y controles 
sanos (59). Además se analizaron los niveles de MASP-2 y 5 polimorfismos del gen 
MASP2 (Thr73Met, Arg84Gln, Arg103Cys, Asp105Gly, Pro111Leuc) en 40 pacientes 
con tuberculosis y en 50 contactos sanos y en la misma cohorte de pacientes con lupus y 
sanos analizada previamente. Casi todos los participantes eran caucásicos.  
Resultados: LXPA/HYPA productor de bajos niveles de MBL fue 
significativamente más frecuente en los contactos sanos comparado con los pacientes 
con tuberculosis (16.8% vs 6.4%, p=0.03). Pacientes con tuberculosis activa comparado 
con controles sanos tuvieron significativamente niveles más altos de MBL (3420ng/mL 
[10-28415] and 2600 ng/mL [5-20000] respectivamente, p=0.02). Estos niveles altos de 
MBL se relacionaron sobre todo con el diplotipo más prevalente YA/YA.  
En el estudio de lupus LYQC/HYPD, LXPA/LYQC y LYPB/HYPD solo se detectaron en 
pacientes con lupus y todos ellos relacionados con niveles muy bajos de MBL. 
Pacientes con lupus mostraron una tendencia a presentar más déficit grave de MBL 
comparado con los controles sanos (25.6% y 13.6% respectivamente, p=0.19). En los 
 12 
dos estudios se obtuvo una clara relación entre los genotipos del exon 1 y del promoter 
de la MBL2 y los niveles de MBL.   
La variante Asp105Gly del gen MASP2 fue la única que se encontró entre los 
participantes de los dos estudios. No se obtuvo relación entre la presencia de esta 
variante alélica y el desarrollo de tuberculosis o lupus. No se obtuvieron diferencias 
entre los niveles de MASP-2 o el déficit moderado o grave de MASP-2 y los pacientes 
con tuberculosis o contactos sanos. Sin embargo si se vió una tendencia a mayor déficit 
grave de MASP-2 en el grupo de pacientes con lupus comparado con los sanos (2/0).   
Conclusiones: el diplotipo LXPA/HYPA, productor de altos niveles de MBL fue 
significativamente más frecuente en los controles sanos, comparado con los pacientes 
con tuberculosis sugiriendo una función protectora frente a la tuberculosis, no descrito 
previamente. Pacientes con lupus mostraron una tendencia a mayor déficit grave de 
MBL comparado con controles sanos y determinados genotipos productores de bajos 
niveles de MBL solo se encontraron en pacientes con lupus, por lo que podría ser un 
factor de riesgo para desarrollar lupus. La variante Asp105Gly del MASP2 fue la única 
detectada. Más estudios son necesarios para entender el papel de las MBL y de las 
MASP en la tuberculosis y en el lupus.  
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4. Introduction 
In mammals, the innate immunity is permanently active to preserve the integrity 
of the host organism. Innate immunity constitutes the first line defence against 
pathogens. It is required to generate a specific adaptive immune response and 
participates in remodelling tissues, in angiogenesis and in clearance of apoptotic or 
necrotic cells. The innate immune system's key components are phagocytes and natural 
killer cells, natural antibody production, cytokines and other soluble factors, and the 
complement system. Complement activation can occur through the classical, the 
alternative or the lectin pathway, and mainly functions in pathogen opsonization, 
chemotaxis, activation of phagocytes, and direct pathogen lysis through the formation of 
the membrane attack complex [1]. 
MBL is an important component of the innate immune system. It has four 
distinct functions: activation of the lectin-pathway of the complement system, direct 
promotion of opsonophagocytosis independent of complement activation, modulation of 
the inflammatory response, and promotion of apoptosis. Because of its clinical role, 
MBL has been the focus of interest over the past 20 years, primarily through 
epidemiological studies. Susceptibility to and the course of different types of infections 
as well as autoimmune, metabolic and cardiovascular diseases may be influenced by 
genetically determined variations in MBL serum concentrations. [2]. Defects in MBL 
could entail a deficient clearance of apoptotic material, thus increasing exposure to 
autoantigens that drive the production of autoantibodies, and further tissue inflammation 
[2-4].  
a) MBL genetics 
MBL production is controlled by the MBL2 gene that lies in chromosome 10, 
and polymorphisms of the structural regions of the gene or its promoter have been 
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associated with relative or absolute serum MBL deficiencies [2]. Three mutations in 
exon 1 of the MBL2 gene are currently known: codon 52 (rs5030737; C>T; Arg>Cys), 
called D variant, codon 54 (rs1800450; G>A; Gly>Asp), called B variant, and codon 57 
(rs1800451; G>A; Gly>Glu), called C variant. B, C and D variants are referred to 
collectively as O, while A is referred to as the wild-type. Individuals with the wild-type 
genotype (A/A) have generally high MBL levels; heterozygotes A/O have about 10% of 
wild-type serum concentrations of MBL, and homozygotes O/O have very low or absent 
MBL levels [5]. Other polymorphisms in the promoter 1 region modulating MBL levels 
have been identified at position -550 (rs11003125; G>C; polymorphism H/L) and -221 
(rs7096206; C>G; polymorphism X/Y) [6], and a P/Q variant has been identified in a 
5´untranslated region at position +4 (C>T, rs7095891) [7]. Because of a strong linkage 
disequilibrium between the polymorphisms which are present in the promoter and the 
structural variants in exon 1 of the MBL2 gene, only seven common haplotypes have 
been described (HYPA, LYPA, LXPA, LYQA, HYPD, LYPB, and LYQC) and there are 
therefore 28 possible diplotypes, the frequency of which varies among populations [6]. 
The combination of exons and promoter polymorphisms results in up to 1000-fold 
variations in MBL concentrations in different individuals. Among haplotypes carrying 
the wild-type A allele, HYPA and LYQA are related to high MBL levels, LYPA is related 
to medium to low levels, and LXPA is related to low serum MBL levels [5, 7,8].  
b) The impact of MBL levels on infections 
Low serum MBL has been described as the world's most common immune 
deficiency. MBL deficiency typically manifests as recurrent infections of the respiratory 
tract in the paediatric population aged 3 months to 2 years. MBL deficiency in adults 
may be important during the initial stages of an infection before the specific immune 
response is activated, and this defect may become more relevant in association with an 
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additional immune defect such as systemic lupus erythematosus, chemotherapy-induced 
neutropenia, AIDS or cystic fibrosis [9]. An association between MBL deficiency and 
susceptibility to and severity of a wide range of infectious diseases (Mycoplasma 
infection, hepatitis B and C, HIV infection, schistosomiasis [10], and pneumonia [11]) 
has been described in adults, but results are controversial. 
Ethnic differences have also been studied, and it has been observed that low 
MBL level-related genotypes are present in 10% of Caucasians and in up to 40% of 
Africans [7,12,13]. This has been related to the possibility that low MBL levels could 
protect against intracellular infections like malaria or tuberculosis [9,13,14]. This can be 
explained analyzing MBL activity. MBL binds to specific carbohydrate structures on 
various pathogens, including MTB. Together with the MASP, MBL activates the lectin 
pathway of the complement, opsonizing and facilitating the phagocytosis of 
microorganisms by macrophages. Thus, low MBL serum levels could confer resistance 
against mycobacteria by impairing opsonization. Some investigators have suggested 
that low MBL producer genotypes could be protective against developing TB disease 
[14-18], but other studies and a recent Chinese meta-analysis [19,20] have concluded 
that the exon1 mutant B allele carriers, who are low MBL producers, have an increased 
risk of TB.  
c) The impact of MBL levels on SLE 
The role of the MBL pathway in complement activation and in the clearance of 
apoptotic cells suggests that genetic variability in MBL may be involved in the 
pathogenesis of SLE. SLE is a multifactorial disease and susceptibility is related to 
genetic, hormonal, immunological, and environmental factors. A strong genetic link has 
been identified through the use of genome-wide association and family studies, and 
more than 30 SLE related loci have already been identified [21]. 
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On the one hand, previous studies have shown an association between MBL 
deficiency and SLE, SLE severity, renal disease [2,22,23,], infections [24], thrombosis, 
and antiphospholipid syndrome [23], while others have found an association restricted 
to European-derived patients [8,25], and a meta-analysis showed that MBL variant 
alleles were a significant SLE risk factor [22]. On the other hand, a study in Spain did 
not find a significant association between SLE and MBL deficiency [26]. There have 
been few MBL and SLE studies in the Spanish population [1,23,26]. 
d) MASP-2 genetics 
Complement activation of the lectin pathway is triggered by the binding of MBL 
to the surface carbohydrates of different microorganisms. This leads to the cleavage of 
C4 and C2, and the formation of the C3 convertase (C4b2a), the opsonization and 
phagocytosis of target microorganisms, and the formation of the membrane attack 
complexes. In human plasma, MBL is found in association with four structurally related 
proteins: MASP-1, MASP-2, MASP-3 (the MBL-associated proteases) and MAp-19. 
MASP-2 is believed to be the most important for complement activation and generation 
of the C4b2a [27, 28]. Polymorphisms of the MASP2 gene are known to cause impaired 
complement activation [29], due to the impossibility of forming a complex between 
MASP-2 and MBL [30]. 
An inherited MASP-2 deficiency was described for the first time in 2003. The 
patient was homozygous for the Asp105Gly mutation in exon 3 of the MASP2 gene in 
the CUB1 domain, which led to a reduction in MASP-2 concentrations and interrupted 
the lectin pathway of the complement activation. This patient had a history of infections 
and inflammatory diseases [30].  
One study suggested a low clinical penetrance of the MASP-2 deficiency as 
there are healthy subjects with a MASP-2 deficiency without infections, autoimmune or 
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inflammatory disorders [15]. Despite its low penetrance, MASP-2 deficiency was 
included in the list of primary immunodeficiencies and it has been associated with SLE 
and infectious diseases [31]. 
Other different single nucleotide polymorphisms have been described in exon 3 
of the MASP2 gene among individuals from Africa [28], Europe and Brazil [32]: 
Pro111Leu, Arg84Gln, Thr73Met and Arg103Cys [28,33], but none have been related 
to MASP-2 deficiency.  
e) The impact of MASP-2 levels on infections 
The impact of MASP-2 levels on the development of infections is controversial. 
Following allogeneic stem cell transplantation, a cohort of adult patients heterozygous 
for Asp105Gly MASP2 variant was found to have an increased risk of invasive 
aspergillosis, but not of bacterial or viral infections [33]. Other studies have analyzed 
the relationship between the same MASP2 variant and community-acquired pneumonia 
[11], pneumococcal bacteraemia in HIV-infected patients [35], renal transplant 
recipients with infectious complications [36] or patients with sepsis [33], finding no 
differences. No studies have been published in tuberculosis.  
f) The impact of MASP-2 levels on SLE 
MASP-2 data in inflammatory disorders are scarce and conflicting. A study 
related Asp105Gly with inflammatory diseases [30], but another study in a Spanish 
cohort did not find a relationship between this allelic variant and the development of 
SLE [15]. Recently, another study found lower MASP-2 levels in rheumatoid arthritis 
patients than in healthy controls [37]. 
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5. Objectives 
The objective of this study is to analyze the relationship between MBL2 
genotypes, including exon 1 and promoter polymorphisms, MBL serum levels, MASP2 
polymorphisms and MASP-2 levels, and the susceptibility to develop: 
- TB disease, in a cohort of TB patients and healthy house-hold contacts of these 
TB patients.  
- SLE, SLE-specific clinical manifestations, and severe disease  in a cohort of 
SLE patients and a healthy control group. 
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6. Patients, material and methods 
6.1. Patients 
a) Participants of the TB study 
Spanish patients with active TB disease, attending the TB Unit in Son Llàtzer 
Hospital in Palma de Mallorca during two periods (January 2007-December 2008 and 
January 2010-December 2012) were included in the MBL study and only those from the 
second period were included for the MASP analysis. TB diagnosis was confirmed by 
the growth of MTB in culture or by clinical, radiological and histological findings with 
improvement with the anti-tuberculous therapy. Patients with pulmonary TB, extra-
pulmonary TB (one extrapulmonary organ affected) and miliary TB (with lung and at 
least another viscera affected) were recruited. In addition, HHC-persons genetically 
related or not to the patient, who at the time of the diagnosis of tuberculosis, had 
cohabited with the patient for at least two months, evaluated at our unit, were included 
in the study; none of them had previously received isoniazid treatment nor had 
developed TB disease. A tuberculin-skin test was done to all the participants [38]. 
b) Participants of the SLE study 
Patients visited between 2010 and 2012 at the Son Llàtzer Hospital in Palma de 
Mallorca with a diagnosis of SLE that fulfilled American Rheumatology SLE criteria 
[39] and a control group of healthy volunteer blood donors were included in the study.  
A code was assigned to each participant, and demographic, clinical and analytical data 
(cell blood count, complement, antiDNAantibodies and urinary sediment), as well as 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [40] at inclusion 
were entered into an anonymous database. A subgroup of Caucasian subjects was 
performed.  
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6.2. Material and methods 
Demographical and epidemiological data were obtained from the medical 
records. The study was approved by the Ethics Committee of the Balearic Islands and 
all participants provided written informed consent.  
a) Blood sampling protocol 
The blood was aseptically collected into plain and ethylenediaminetetraacetic 
acid tubes. For all samples, serum was separated immediately and transferred into 
cryovials and preserved at -80°C for further testing.  
b) MBL quantification 
MBL serum concentrations were determined by enzyme-linked immunosorbent 
assay (ELISA) performed in microwells coated with a monoclonal antibody against the 
MBL carbohydrate-binding domain in a commercial kit (oligomerized mannan-binding 
lectin; AntibodyShop®, Gentofte, Denmark). MBL serum concentrations were 
expressed as ng/mL. 
c) MBL2 SNP genotyping 
EDTA blood samples were used for genomic DNA isolation. Genomic DNA 
was extracted using the Maxwell® 16 Blood DNA Purification Kit (Promega, United 
States). Six SNP in the MBL2 gene (-550  G/C [rs11003125], -221 C/G [rs7096206], +4 
C/T [rs7095891], codon 52 CGT/TGT [rs5030737], codon 54 GGC/GAC [rs1800450], 
and codon 57 GGA/GAA [rs1800451]) (GenBank accession numbers AF360991) were 
analysed. Genotyping was performed by polymerase chain reaction with sequence-
specific primers (PCR–SSP). Polymorphisms within the promoter and exon 1 of the 
MBL2 gene were analysed, using primer pairs spanning from the promoter region 
through exon 1. The primers used were as follows: MBL2-1F -
GGGAATTCCTGCCAGAAAGTAGAG, MBL2-1RGGA-TCCTAAGGAGGGGTTCATCT, MBL2-2F-
ACTAGTCACGCAGTGTCACAAGGA, and MBL2-2R-CAGGCAGTTTCCTCTGGAAGGTA. In 
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short, 50 ng of genomic DNA were amplified in a 50 µL volume of reaction mixture 
containing 1× PCR buffer, 2.5 mM of MgCl2, 0.2 mM of dNTPs, 0.5 mM of each 
primer, and 1 U GoTaq® Hot Start Polymerase (Promega, United States) on a T1 
Thermocycler (Biometra, Germany). Thermal cycling parameters for amplification of 
both regions were 95°C for 10 minutes (initial denaturation); 40 cycles of 30 seconds at 
95°C (for denaturation), 30 seconds at 55°C (for annealing), 45 seconds at 72°C (for 
extension); and 10 minutes at 72°C (for final extension). PCR products were cleaned up 
by use of Excela Pure 96-Well UF Plate (EdgeBio, United States), and 1 μL of the 
purified product was directly used as a template for sequencing, using the BigDye 
terminator v. 3.1 cycle sequencing kit (Applied Biosystems, United States) on an ABI 
3730XL DNA sequencer, following the manufacturers’ instructions. Polymorphisms 
were identified by assembling the sequences with respective reference sequences 
(NG_008196.1), using Sequencer, version 5.0 (available at: http://genecodes.com/), and 
were reconfirmed visually from their respective electropherograms.  
d) MASP-2 quantification  
MASP-2 serum concentrations were determined by an enzyme-linked 
immunosorbent assay (ELISA) performed in microwells coated with a monoclonal 
antibody against MASP-2 in commercial kits (oligomerized mannan-binding lectin; 
AntibodyShop®, Gentofte, Denmark and MASP2 ELISA kit, Cusabio, E-17966H), 
following the manufacturers´ instructions. MASP serum concentration was expressed as 
ng/mL.  
Low MASP-2 levels were defined as a concentration ≤75 ng/mL, intermediate 
levels as a concentration >75 ng/mL and ≤ 200ng/mL and high levels as a concentration 
> 200ng/mL [41].  
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e) MASP2 SNP genotyping 
EDTA blood samples were used for genomic DNA isolation. Genomic DNA 
was extracted using the Maxwell® 16 Blood DNA Purification Kit (Promega, United 
States). For the MASP2 genotype, genotyping was performed by polymerase chain 
reaction with sequence-specific primers (PCR–SSP). Five SNP in the MASP2 gene 
(Thr73Met [rs61735601], Arg84Gln [rs61735600], Arg103Cys, Asp105Gly 
[rs72550870], Pro111Leu [rs56392418]) were analyzed. The primers used were as 
follows: MASP2-1F GCCTCTACTTCACCCACTTCGAC, MASP2-1R 
GCCTGGCCTAAGACAGAGTTACC. In short, 50 ng of genomic DNA were 
amplified in a 50 µL volume of reaction mixture containing 1× PCR buffer, 2.5 mM of 
MgCl2, 0.2 mM of dNTPs, 0.5 mM of each primer, and 1 U GoTaq® Hot Start 
Polymerase (Promega, United States) in a T1 Thermocycler (Biometra, Germany). 
Thermal cycling parameters for amplification of both regions were 95°C for 10 minutes 
(initial denaturation); 40 cycles of 30 seconds at 95°C (for denaturation), 30 seconds at 
55°C (for annealing), 45 seconds at 72°C (for extension); and 10 minutes at 72°C (for 
final extension). PCR products were cleaned up by use of Excela Pure 96-Well UF Plate 
(EdgeBio, United States), and 1 µL of the purified product was directly used as a 
template for sequencing, using the BigDye terminator v. 3.1 cycle sequencing kit 
(Applied Biosystems, United States) on an ABI 3730XL DNA sequencer, according to 
the manufacturers’ instructions. Polymorphisms were identified by assembling the 
sequences with respective reference sequences (NG_007289.1), using Sequencer, 
version 5.0 (available at: http://genecodes.com/), and were reconfirmed visually from 
their respective electropherograms. 
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6.3. Statistical analysis 
First, a descriptive analysis of the different populations of the study was 
performed. Qualitative data are expressed as percentages. Quantitative data are 
expressed as mean (+/- SD) or median and range. 
Means are compared by t-test (or Mann Whitney U-test if the sample does not 
have a normal distribution). Diplotype frequencies were compared between cases and 
controls by X
2
 test or Fisher´s exact test when necessary. P values with Yates correction 
and odds ratio (OR) with 95% confidence interval were calculated. Statistical 
significance was taken as a p-value less than 0.05. The Pearson correlation coefficient 
was calculated to measure the correlation between MBL and MASP-2 levels. The 
analysis was carried out with SPSS 13.0 and EPIDAT 3.1 software.  
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7. Results 
7.1. MBL in TB 
Seventy-nine patients with the diagnosis of active TB and 120 HHC were 
recruited. Due to technical problems, MBL levels were available in 73/79 TB patients 
and 104/120 HHC and complete genotyping results were obtained in 76/79 patients and 
in 106/120 HHC.  
Median age was 45 (18-84) years in the TB patients and also 45 (18-94) years in the 
HHC. Fifty-nine TB patients (74.7%) were men. Fifty-eight (73.4%) had pulmonary TB 
and 21 (26.6%) extrapulmonary or miliary TB. Eighty-four (70%) of the HHC had 
positive TST test.  
a) MBL2 exon 1 genotype frequencies  
All the structural genetic variants of the MBL gene were within the range of Hardy-
Weinberg equilibrium. The most frequent allele found in both groups was the wild type 
allele A/A. The complete MBL2 genotype frequencies are described in table 1.  
b) MBL2 complete (exon 1 and promoter) diplotypes  
The results are shown in table 2. HYPA was the most frequent haplotype (91/182 
subjects), followed by LXPA (83/182 subjects) and LYQA (70/182 subjects). HYA 
haplotype was present in 36/76 (47.4%) in the TB cases and in 54/106 (50.9%) HHC, 
finding no statistical significant difference.  LYQA/HYPA was the most frequent 
diplotype among TB patients and median MBL levels among these patients were high 
(6644ng/mL (1660-20000). LXPA/HYPA was significantly more frequent in HHC (table 
2) and it was also associated with high MBL levels, 3600n/mL (1000-12800). 
LYQA/HYPA was present in 12/57 (21.5%) pulmonary TB cases, 1/8 (12.5%) miliary 
TB and in none of the cases of extrapulmonary TB.  
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c) MBL levels 
Comparing MBL levels in TB patients and HHC it was significantly higher in TB 
patients (3460ng/ml [10-28415] and 2570 ng/ml [5-20.000] respectively, p=0.002). 
Patients with pulmonary TB had significantly higher MBL levels compared to patients 
with extrapulmonary TB (3980 ng/mL [20-28415] and 1100 ng/mL [10-8000] 
respectively, p=0.02). On the other hand, MBL levels did not differ significantly, when 
comparing pulmonary and miliary TB (miliary TB 2197 ng/mL [55-12800], p=0.3).  
d)  MBL2 genotype and MBL levels 
There was a strong correlation between MBL2 Exon 1 and promoter genotype and 
MBL levels (Figure 1). For simplification purposes, only X/Y polymorphism from the 
promoter region was considered. Numerical results are described in table 3.  
e) HIV infection 
Eighteen of 79 TB patients (22.8%) were infected with HIV and 3 of 120 (2.5%) 
among the HHC. MBL levels in HIV TB patients and non HIV patients did not differ 
significantly (2353.5 ng/mL [20-28415] and 3800 ng/mL [10-20000] respectively, 
p=0.87). MBL2 genotyping could be done only in 16 patients and there were no 
significant differences in complete diplotype depending on HIV status.  
7.2. MBL in SLE 
Thirty-nine SLE cases and 59 healthy controls were included. There were 37 
(94.9%) women in the SLE group and 55 (93.2%) in the control group. Gender 
distribution was the same in both groups. All the controls were Caucasians (58 from 
Spain, one from Germany). Among the cases, there were 35 Caucasians (28 Spanish, 
one Irish, one Polish, three Argentinian, one German and 1 Brazilian), three Nigerian 
and one Bolivian. 
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A descriptive analysis of SLE disease activity of the SLE patients was done 
(Table 4).   
MBL levels could not be determined in one of the cases due to technical 
problems. 
a) MBL2 Exon 1 frequencies and allele B 
All the structural genetic variants of the MBL gene were within the range of Hardy-
Weinberg equilibrium. 
There were no statistical significant differences between MBL 2 genotypes in SLE 
patients compared to controls (Table 5). Allele B was analysed in SLE patients 
compared to controls, 16 [(33.30%]) and 14 [(23.70%]) respectively, but no statistical 
significant result was found.  
Considering exclusively Caucasian subjects, the wild-type allele was more frequent 
in the control group compared to SLE patients (41 [69.5%] vs. 18 [51.4%] respectively) 
but without reaching statistical significance p=0.1. Allele B was more frequent in the 
SLE group compared to the controls (13 [37.1%] and 14 [23.7%] respectively), but 
without reaching statistical significance (p=0.25).  
b) MBL 2 complete (exon 1 and promoter) diplotypes 
MBL 2 diplotype frequencies for both SLE and control subjects are shown in Table 
6.  
HYPA and LXPA were the most frequent haplotypes (44/98 subjects respectively), 
followed by LYQA, in 40/98 subjects. LYQA/HYPA was the most frequent diplotype  in 
SLE cases and in controls (6/39 [15.4%] and 12/39 [20.2%] respectively) with a  
median  MBL level of  4160 ng/mL (2520-5040) in cases and 3570 ng/mL (1660-
10194) in controls. The following diplotypes were only detected in patients with SLE: 
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LYQC/HYPD (one case), LXPA/LYQC (one case) and LYPB/HYPD (two cases), and all 
of them had very low MBL levels (20, 20, 10 and 2 ng/mL respectively).  
c) MBL levels 
Median MBL level in SLE patients and controls was 1675ng/mL (2-9726) and 2320 
ng/mL (4-11534) respectively, showing no statistically significant difference (p=0.62). 
The relationship between gender and MBL levels is shown in table 7. 
Very low MBL levels (≤100 ng/mL) were observed in 18 subjects; 10 cases (25. 
6%) and 8 controls (13.6%) respectively (p=0.19). Levels > 1000 ng/mL were found in 
22 (57, 9%) SLE patients and 41 (69.5%) healthy controls (p=0.34).  
In the Caucasian subjects, severe MBL deficiency was found in 9 cases (25.7%) and 8 
controls (13.6%) respectively, finding no statistically significant difference (p=0.2). 
Levels >1000 ng/mL were found in 19 cases (54.3%) and 41 controls (69.5%) (p=0.27). 
As in the overall group, it was not possible to find a statistically significant difference in 
median MBL levels by comparing cases and controls.  
d) MBL 2 genotype and MBL levels 
There was a correlation between exon 1 and promoter MBL 2 genotype and MBL 
levels (Figure 2 and table 8).  
In the Caucasian subgroup there was no statistically significant difference. 
Analysing together cases and controls, wild-type genotype YA/YA showed very high 
MBL levels (> 1000 ng/mL) except for one patient, who had a moderate deficiency, and 
genotype O/O showed very low levels (< 100 ng/mL). The same results were found in 
the subgroup of Caucasian participants. 
e) MBL levels and SLE activity, SLE manifestations, reactant phase proteins, and 
complement (CH50, C3, C4) levels. 
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SLE clinical manifestations depending on MBL2 polymorphisms are shown in 
Table 9.  
There was no correlation between SLE clinical manifestations and exon 1 variant 
alleles (A/O or O/O), nor could we find a correlation between MBL levels and reactant 
phase proteins (erythrocyte sedimentation rate or C- reactive protein [CRP]). 
Complement deficiencies (C3, C4 and CH50) were analysed together and one by one to 
search for a relationship with MBL genotypes (A/A versus A/O or O/O) and no 
statistically significant difference was found.  
f) MBL levels and drugs 
Thirty (76.9%) SLE patients were receiving immunosuppressive drugs. The 
different treatments are represented in Figure 3. There was no relationship between 
MBL levels and the use of immunosuppressive drugs.  
 
7.3. MASP in TB 
Forty-nine TB patients and 50 HHC were included. Mean age was 48.6 (14.9) in TB 
patients and 47.9 (14.4) in HHC, finding no statistical significant difference. There were 
significantly more males among cases than controls, 40 (81.6%) and 22 (44%) 
respectively, p 0.0003, OR 5.66, CI 2.27-14.1. Toxic consumption (tobacco and heavy 
alcohol) was detected in 10 (20.4%) patients and 12 (24%) contacts, finding no 
statistical significant difference. Seven-teen (34.7%)  TB patients and 5 (10%) HHC 
were infected with HIV, p=0.0031. Four (8.2%) patients and 6 (12%) HHC were 
diabetic finding no statistical significant difference. Only 2 (4.1%) TB patients had a 
hematologic or solid neoplasia and none of the HHC. Pulmonary TB was diagnosed in 
39 (79.6%) patients, in 8 (16.3%) patients miliary TB and in 2 (4.1%) lymphadenitis. 
MASP2 genotype could not be determined in 6 participants (3 patients and 3 controls).  
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a) MASP2 polymorphisms 
No statistical significant differences were found in MASP2 genotype between TB 
patients and HHC. The allelic variant Asp105Gly was found in two participants. The 
first participant was a patient with TB and HIV infection, 262.6 ng/mL was the MASP-
2 level and 4000 ng/mL the MBL levels. The second one was a healthy HHC, with 
129.8ng/ml as MASP-2 level and 100ng/ml as MBL level. The allelic frequency was 
1.07. The other allelic variants (Thr73Met, Arg84Gln, Arg103Cys, Asp105Gly or 
Pro111Leu) were not found in any of the participants.  
b) MASP-2 levels 
MASP-2 levels were determined in all the participants. Globally, median MASP-2 
levels were 235.09 ng/mL [67. 1- 532.9] and median MBL levels (in this part) were 
2260.0 ng/mL [4.0-9400.0]. There was a weak negative correlation between MASP and 
MBL levels (r: -0.213). No gender-related statistical significances were observed in 
MASP-2 levels. Mean MASP-2 levels in TB patients was 231.1ng/ml (83.6) and 270.3 
(101.1) in HHC, p=0.063. Excluding HIV-infected patients, there was a trend towards 
lower MASP-2 levels in TB patients compared to HHC: 226 ng/mL (86.8) and 270.7 
ng/mL (104.3) respectively, p=0.053. Mean MASP-2 levels in pulmonary TB were 
236.5ng/ml (83.8) and 248.1 (87.3) in miliary TB, without reaching statistical 
significance (p=0.72). Normal MASP-2 levels were found in 66 participants (66.67%) 
and moderate MASP-2 deficiency in 33 (33.33%). MASP-2 levels related to TB 
disease, HIV status or MBL deficiency are shown in table 10. A severe MASP-2 
deficiency (<75ng/mL) was found in 1 (2.04%) patient with TB and high MBL levels 
(3800ng/mL). 
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7.4. MASP in SLE 
Thirty-nine SLE cases and 59 healthy controls were included, the same as in the 
MBL study. There were 37 (94.9%) women in the SLE group and 55 (93.2%) in the 
control group.  
a) MASP2 polymorphisms 
The allelic variant Asp105Gly in the MASP2 gene was found in 5 controls (8.47%), 
namely Spanish Caucasians, and was absent in the SLE group.  All of them were 
heterozygous (Table 11). Thus, it was detected among Caucasians with an allelic 
frequency of 2.66%.  
As there was no mutated allele in the SLE group, its relationship with the severity of 
the disease could not be analyzed. 
The allelic variants Thr73Met, Arg84Gln, Arg103Cys and Pro111Leu were absent 
in the overall group of subjects. 
b) MASP-2 levels 
Overall mean MASP-2 level was 287.94 ng/mL (SD 183.60). Mean MASP-2 level 
in SLE patients was 333.12 ng/mL (SD 265.71) and 258.08 ng/mL (SD 88.55) in 
controls (p =0.08). No statistically significant difference was found when MASP-2 
levels were compared between subjects heterozygous for Asp105Gly and those with the 
wild-type genotype (220 ng/mL [SD 44.6] and 291 ng/mL [SD 187.6] respectively, 
p=0.3).  
MASP-2 levels above 200ng/mL were found in 69 (70.4%) participants, 27 (69.2%) 
cases and 42 (71.2%) controls (p=0.96). Twenty seven (27.6%) participants had 
moderate MASP-2 levels, 10 (25.6%) SLE patients and 17 (28.8%) healthy controls 
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(p=0.9). Two participants (2.04%) were found to have very low MASP-2 levels, both 
SLE patients.  
When comparing MASP-2 level according to ethnicity, mean MASP-2 in 
Caucasians was 284.64 ng/ml (SD 185.89) and 365.42 ng/ml (SD 101.77) in non 
Caucasians, p= 0.21. 
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8. Discussion 
In our study we evaluated MBL levels and a complete MBL2 genotypic profile 
including promoter polymorphisms and MASP-2 levels and MASP2 polymorphisms in 
Spanish TB patients and in HHC, exposed to MTB but who have not developed the TB 
disease and in SLE patients and healthy controls. Globally LXPA and HYPA were the 
most frequent haplotypes in both parts of the study. The diplotype LXPA/HYPA was 
significantly more frequent in HHC than in TB patients, suggesting a protective role 
against the development of TB disease. Diplotypes that were only found in SLE patients 
(LYQC/HYPD, LXPA/LYQC and LYPB/HYP) were associated with very severe MBL 
deficiency, suggesting a higher risk to develop SLE.  
There were no statistically significant differences in MASP 2 levels or in the 
presence of the allelic variant between TB patients and HHC or SLE patients and the 
control group. When HIV infection was excluded, a trend towards lower MASP-2 levels 
was observed in TB patients compared to HHC. A tendency towards a higher frequency 
of severe MASP-2 deficiency among SLE patients compared to the control group (2/0) 
was found. No other allelic variants studied could be found among the cohort.  
a) MBL in TB 
According to other studies [42,43], LXPA and HYPA were the most frequent 
haplotypes. The biological meaning of the finding that the high MBL producer genotype 
LXPA/HYPA was significantly more frequent among HHC than in TB patients, 
described for the first time in literature, cannot be related to differences in serum MBL 
because the HYA haplotype has been related to high serum MBL levels [5]. One 
explanation could be a linkage disequilibrium among this alleles and other genes in 
chromosome 10, such as MRC1, that encodes for mannose receptor C-Type lectin, that 
have been suggested to be associated with altered susceptibility to mycobacteria [44]. 
 33 
A previous study associated HYPA haplotype also with protection against 
another infection as schistosomiasis in Nigeria [10]. In one study developed in Spain 
[43], no diplotype was associated with TB; however HYPD haplotype was more 
frequent in the control group compared to TB patients.  
Analyzing MBL levels and according to other studies [16,45,46], we found 
significantly higher serum MBL levels in TB patients, especially those with pulmonary 
TB, compared to HHC. It is mainly related to the most prevalent diplotype, wild-type 
YA/YA. It has been previously described, that high MBL levels are mostly related to the 
wild-type MBL2 genotype A/A or YA/YA [17, 47], but we could not demonstrate that the 
wild-type genotype was more frequent in patients than in HHC. On the contrary, we 
could not find that low MBL2 producer genotypes were more frequent among HHC 
conferring TB protection. Some studies suggest that low MBL producer genotypes 
could confer protection against TB [14-18], however data are contradictory; a Chinese 
article [19] and a recent Chinese meta-analysis [20] find that Exon 1 mutant Allele B 
carriers, related to low MBL levels, have an increased risk of developing TB.  
According to this results another study with an Italian population described, that the 
wild-type haplotype HYA (a high producer haplotype), could be protective against 
pulmonary TB [48]. Moreover, this haplotype HYA has been associated with reduced 
risk of bacterial, viral or fungal infection in allogenic hemopoietic stem cell 
transplantation [49]. However, in our study HYA haplotype was not more frequent 
among the HHC. As explained, there is controversy and no consistent association 
between MBL2 genotype and TB infection can be determined, what has been confirmed 
in a recent meta-analysis [45]. This analysis was limited by the heterogeneity in the 
designs of the included studies and most of it did no report a complete MBL2 
genotyping.  
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Pulmonary TB has been related in some studies with higher MBL levels 
compared to extrapulmonary TB [16], different to our study, were no statistical 
significant differences were found. High MBL producer genotype was only found in 
pulmonary TB cases and not in the extrapulmonary TB patients, thus, the relationship 
cannot be excluded. Moreover, pulmonary TB has been related to higher expression of 
acute phase reactants and proinflammatory cytokines as interferon gamma compared to 
extrapulmonary TB [50]. Thus, it could be interesting to determine MBL levels in the 
TB patients at the end of the treatment to analyze its role as an acute-phase reactant.  
In HIV positive TB patients a significantly higher frequency of YA/YA diplotype 
associated with very high MBL levels has been described [51] suggesting that MBL 
deficiency could be a protector factor against TB, as in other studies [52]. However, 
maybe related to the small sample of HIV patients in our study, we could not find any 
relation between HIV status and MBL levels or MBL2 genotype. 
b) MBL in SLE 
As in the TB study HYPA and LXPA were the most frequent haplotypes, which 
is in agreement with previous studies in the general European population, including a 
study in Caucasians (Spain) [1,42,43]. In the same way, the wild-type genotype A/A was 
the most frequent genotype in both, the general population and the SLE patients [2]. 
Several studies have suggested  that genotypes related to very severe MBL deficiency 
are a risk factor for developing SLE in different ethnic populations [22,53]; however, 
the majority of previous studies did not report a complete MBL2 genotyping, promoter 
allelic variants were rarely analysed [54-56] and results are contradictory. An 
association between allele B in codon 54 of exon 1 and SLE has been extensively 
described [22,54,57]. In a recent study in Indian SLE patients, it was found that 
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genotypes producing low MBL levels, especially the presence of allele B, but also with 
allele X at position -221, were significantly more frequent in SLE patients compared to 
healthy participants [54]. A meta-analysis confirmed identical results and added allele L 
at position -221 as a risk factor for developing SLE [22]. In our study we also found in 
Caucasians a tendency to a higher incidence of allele B in the SLE group compared to 
the controls, although without reaching a statistical significance. Other studies 
conducted in the Canary Islands, China, and Hungary found no statistically significant 
differences for  allele frequencies in  exon 1  and  promoter  MBL2 genotype comparing 
SLE patients and  a control group, but a trend towards a higher frequency of  low MBL 
producer genotypes in SLE patients was generally found [26,56,58]. 
MBL serum levels largely depend on MBL2 exon 1 and promoter genotype, but 
there is no exact correlation between MBL2 genotypes  and MBL levels probably 
because of other factors such as hormones or acute inflammation that modulate MBL 
production [1]. As said before, MBL has been considered an acute phase reactant, but 
studies are conflicting [1,53,59] and one showed that MBL did not act as an acute phase 
reactant in pneumonia [60] for example. Likewise, our study did not find any 
relationship between MBL levels and acute phase reactants such as CRP and globular 
sedimentation rate.  
MBL has been considered a modulator of disease activity in SLE. On the one 
hand, a higher prevalence of cardiovascular, renal or severe disease was observed in 
patients carrying low-MBL producer genotypes compared to those carrying high MBL 
producer genotypes [23,24]. On the other hand, some studies have concluded that high 
MBL levels were associated with SLE nephritis and other SLE manifestations [59, 61]. 
In our study, most of our patients had a low SLEDAI score (between 0-2) and we did 
not find any significant relationship between MBL levels and disease severity, nor 
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between any allelic variants in exon 1 and clinical manifestations. Homozygosity for 
MBL variant alleles have been associated with infections in SLE patients [62,63], but 
we could not evaluate infections in this transversal study. MBL is associated with 
complement activation through the lectin pathway and therefore low complement levels 
in patients with high MBL could be expected, as it has been described in SLE in an 
Indian study [59], but results are contradictory [23,62]. In our study, we did not find any 
association between the complement system and MBL levels.  
c) MASP in TB 
The Asp105Gly MASP2 variant frequency in our study was 2.02%, similar to 
that previously reported among Spanish populations [28,32], but lower than the 3.6% 
reported in a Danish cohort [41]. The other allelic variants analyzed were not found in 
any of the participants, variants described previously in an African but not Spanish 
population [28]. The relation between Asp105Gly and infections is controversial. One 
study found an increased risk for aspergillosis in stem cell transplant recipients [34], 
however, other studies did not find an increased frequency of Asp105Gly in adult 
patients with community-acquired pneumonia [11], and pneumococcal bacteremia in 
HIV infected patients [35] or sepsis [34].  Other SNP of the MASP2 gene have also 
been studied, determining it as a risk factor for leprosy [64] or hepatitis C infection [65]. 
This is the first study analyzing the relationship between MASP2 polymorphism and 
TB.  
Analyzing MASP-2 levels, there was no relation with TB disease. Only one 
patient had MASP levels below 75ng/mL, a Spanish TB patient, suggesting a possible 
relation with TB disease.   
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d) MASP in SLE 
MASP-2 deficiency has been described previously in a homozygous patient for 
Asp105Gly mutation with a history of infections and inflammatory disease [30], 
suggesting a possible association between this mutation and autoimmune disease. 
However a Spanish study analyzing Asp105Gly in SLE and healthy subjects 
revealed no difference in allelic frequency between both groups [15], in agreement with 
our findings. Furthermore, another study in patients with different autoimmune disease 
namely psoriasis, did not find a relation between the presence of a mutated Asp105Gly 
allele and the development of the disease [66].  
Asp105Gly allelic frequency varies between populations. Two studies in 
Spanish healthy populations showed Asp105Gly allelic frequencies of 1.44% [28] and 
2.4% [15] respectively, and 2.02% in our TB group, which are slightly lower than the 
frequency we have found in our small sample of Caucasians with and without SLE 
(2.66%). We found no Asp105Gly homozygous individual. Similarly, in a large study in 
Spain, no patients with a SLE diagnosis and only 2/868 healthy controls were found to 
be homozygous carriers [15].   
The allelic variants Thr73Met, Arg84Gln, Arg103Cys, and Pro111Leu were also 
absent in our SLE population as explained in the TB group.  
Mean MASP-2 level was lower than in a healthy Danish population [67]. Two 
individuals in our study had MASP-2 levels below 75ng/mL, which was not found in 
any of the subjects in the Danish study [32].  This could be explained by the inclusion in 
our study of SLE patients, in whom MASP-2 deficiency was more frequent compared to 
the control group, suggesting an association between MASP-2 deficiency and SLE.  No 
correlation was observed between MASP-2 deficiency and the presence of a mutated 
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Asp105Gly allele. This association was described in the first case of MASP-2 
deficiency described [27, 30], but was not reported in all studies [28].  
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9. Limitations 
The small sample size in both parts of the study (the TB and the SLE) is an 
important limitation, which may affect the statistical significance of the results. The 
heterogeneous group of the TB patients, including patients with extrapulmonary TB and 
HIV infection could also interfere in the results.  
In the SLE part, most of the participants had a low SLEDAI score, and 
treatments were heterogeneous. Moreover, SLE participants were of a multiethnic 
origin, whereas the controls were exclusively Caucasians. This is why we created the 
subgroup of Caucasian subjects. However, the results showed the same tendency in both 
analyses. 
MBL levels were only measured at the time of inclusion of the study and were 
not evaluated at the end of the treatment or during an SLE flare. This would have 
allowed to determine their role as an acute phase reactant 
MASP-2 levels can also change over time (15-20% over one year) [67]. In this 
study, MASP-2 concentration was measured only once, which could also be a limitation 
Other new MASP2 allelic variants that have not been determined in this study 
[32,35] may be related to MASP-2 deficiency. Moreover other factors related to the 
lectin pathway such as Map-19 (a shorter spliced product of the MASP2 gene) or the 
activity of the MBL/MASP complex is lacking [41].  
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10. Strengths 
Nevertheless, our study has some important strengths: a complete MBL2 
genotyping of exon 1 and promoter was done, an analysis which is not commonly found 
in published studies; what´s more, very few studies analysing a Caucasian population 
are found in literature.  
It is also important to notice that 5 different MASP2 polymorphisms were 
analyzed, although only one was found.  
To date, this is the first study analyzing the relationship between MASP2 
polymorphisms and MASP-2 in TB and the second cohort including a SLE group and a 
healthy control group.  
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11. Conclusions 
1. The high MBL-producer diplotype LXPA/HYPA was significantly more frequent in 
HHC than in TB patients, suggesting that this diplotype has a protective role against the 
development of TB disease that has not been described previously. 
 
2. LYQC/HYPD, LXPA/LYQC, and LYPB/HYPD diplotypes, which are associated with 
very low MBL levels were only found in SLE patients, and there was a tendency 
towards a higher incidence of allele B in the SLE group compared to the controls. Thus, 
MBL levels and some genetic variants could be a risk factor for developing SLE.  
 
3. Asp105Gly was the only MASP2 variant found in our studies, and no relationship 
with the development of TB or SLE was found.  
 
4. MASP-2 deficiency was more frequent, although not statistically significant, among 
the SLE group, suggesting a relationship with the disease. 
 
5. The precise consequences of MBL2 and MASP2 polymorphisms, and MBL and 
MASP-2 deficiency in relation to the development of TB, SLE or disease progression, 
as well as the role of MBL as an acute phase reactant remain unclear..  
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12. Future directions 
Further studies are needed, including large longitudinal cohort studies with a 
complete genotype profile of the protein (MBL2 exon 1 and promoter) and MBL levels. 
Studies of other components of the lectin pathway, including ficolins, as well as 
functional assessment of the lectin pathway are needed. Moreover, the use of MBL with 
a therapeutic aim, has been analyzed in case reports. Two MBL deficient patients 
received MBL infusions and one of the participants, who had been suffering of repeated 
infections, remained healthy for more than 3 years [68]. Indeed some phase I [69,70] 
and phase II [71-72] studies have been also published, with safety results, but with 
doubts about efficacy.  Moreover, there is one Ib clinical trial still not finished. It is and 
interventional, randomized, safety clinical trial, including MBL deficient patients with 
multiple myeloma, treated with melphalan-based high-dose chemotherapy followed by 
autologous hematopoietic stem cell transplant. Patients are randomized to 0.5 mg/kg, 
1.0 mg/kg, or no recombinant human MBL. The aim of this study is to analyze safety 
and tolerability of intravenous administration of MBL, however the study has been 
completed, but results are still not available.  
Thus, more studies need to be developed to analyze the beneficial or harmful 
effect of MBL and MASP-2 levels and MBL2 and MASP2 polymorphisms. 
Determining the beneficial effect of low MBL and MASP-2 levels would provide 
important insights into the treatment and prevention of severe diseases. Moreover, 
functional assessment of the lectin pathway may be far more useful and clinically 
relevant than MBL level and/or genotype alone.  
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13. Tables 
Table 1. MBL2 genotype frequencies in TB patients and HHC 
MBL2 genotype TB patients 
n (%) 
HHC 
n (%) 
p OR 95% CI 
A/A 48 (63.2) 71 (67) 0.71 0.84 0.45-1.56 
A/O 24 (31.6) 34 (32.1) 0.93 0.97 0.51-1.84 
O/O 4 (5.3) 1 (0.9) 0.19 5.83 0.63-53.2 
Total 76 106    
 
Table 2. Frequencies of complete diplotypes in TB patients and controls 
MBL2 diplotypes TB patients 
n (%) 
HHC 
n (%) 
p OR 95% CI 
LYQA/HYPA 13 (17.1) 15 (14.1) 0,73 1.25 0.55-2.81 
LYQA/LYPB 2 (2.6) 5 (4.7) 0.73 0.54 0.1-2.86 
LYQA/LYPA 1 (1.3) 1 (0.9) 0.62 1.4 0.08-22.73 
LYQA/LYQA 2 (2.6) 7 (4.7) 0.38 0.38 0.08-1.89 
LYQA/HYPD 1 (1.3) 2 (1.9) 0.76 0.69 0.06-7.78 
LYQA/LYQC 1 (1.3) 0    
LYQC/HYPD 1 (1.3) 0    
LXPA/HYPA 5 (6.6) 20 (18.9) 0.03 0.3 0.1-0.84 
LXPA/LYQA 10 (13.1) 10 (9.4) 0.59 1.44 0.57-3.65 
LXPA/LXPA 8 (10.5 6 (5.7) 0.35 1.96 0.65-5.9 
LXPA/LYPB 5 (6.6) 10 (9.4) 0.67 0.67 0.22-2.06 
LXPA/HYPD 2 (2.6) 2 (1.9) 0.86 1.4 0.19-10.2 
LXPA/LYPA 2 (2.6) 3 (2.85) 0.7 0.93 0.15-5.69 
HYPA/HYPA 4 (5.3) 8 (7.5) 0.75 0.68 0.2-2.35 
LYPB/HYPA 8 (10.5) 6 (5.7) 0.35 1.96 0.65-5.9 
LYPB/LYPB 2 (2.6) 1 (0.9) 0.77 2.84 0.25-31.87 
LYPB/HYPD 1 (1.3) 0    
LYPA/HYPA 3 (3.9) 2 (1.9) 0.7 2.14 0.35-13.11 
LYPA/LYPB 2 (2.6) 2 (1.9) 0.86 1.4 0.19-10.2 
LYPA//HYPD 0 2 (1.9)    
HYPD/HYPA 2 (2.6) 3 (2.8) 0.93 0.93 1.51-5.69 
HYPA/LYQC 1 (1.3) 1 (0.9) 0.62   
Total 76 106    
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Table 3. Relation between mean MBL levels and MBL2 genotype (exon1 and promoter) 
in TB patients and HHC  
 Mean MBL levels ng/mL (SD) 
Genotype Patients HHC P 
YA/YA 8387.75 (5945) 5555.03 (3289.62) 0.027 
YA/XA 5691.87 (4221.58) 3710.37 (2309.7) 0.55 
XA/XA 2310 (3199.86) 1200 (978.3) 0.53 
YA/O 1107.88 (1017.66) 951.18 (668.53) 0.6 
XA/O 31.25 (20.97) 100 0.06 
O/O
*  * * * 
    * Cannot be computed because one of the groups is empty 
 
Table 4. Activity index and clinical manifestations in SLE patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MBL 
genotype 
SLE 
n (%) 
Control 
n (%) 
P 
A/A 21 (53.8) 41 (69.5) ns 
A/O 14 (35.9) 17 (28.8) ns 
O/O 4 (10.3) 1 (1.7) ns 
Total 39 59 na 
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Table 5. Frequency of MBL 2 genotypes in SLE patients and in controls 
 
 
 
 
 
 
 
 
Table 6. Frequencies of complete genotypes in SLE patients and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n (%) 
SLEDAI 
0-2 (inactive)            27 (69.2) 
3-4 (mild)                   6 (15.4) 
5-7 (moderate)           2 (5.1) 
>8 (severe)                 4 (10.3) 
Clinical manifestations 
Arthritis                     20 (51.3) 
Nephritis                   11 (28.2) 
Serositis                    14 (35.9) 
Neuropsychiatric        7 (17.9) 
Hematologic             13 (33.3) 
MBL 
genotype 
SLE 
n (%) 
Control 
n (%) 
P 
LYQA/HYPA 6 (15.4) 12 (20.2) ns 
LYQA/LYPB 2 (5.1) 5 (8.5) ns 
LYQA/LYPA 1 (2.6) 1 (1.7) ns 
LYQA/LYQA 2 (5.1) 4 (6.8) ns 
LYQC/HYPD 1 (2.6)  na 
LXPA/HYPA 2 (5.1) 9 (15.3) ns 
LXPA/LYQA 1 (2.6) 6 (10.2) ns 
LXPA/LXPA 3 (7.7) 4 (6.8) ns 
LXPA/LYPB  4 (10.3)     5 (8.5) ns 
LXPA/HYPD 0 1 (1.7) na 
LXPA/LYPA 4 (10.3) 4 (6.8) ns 
LXPA/LYQC 1 (2.6) 0 ns 
HYPA/HYPA 3 (7.7) 1 (1.7) ns 
LYPB/HYPA 4 (10.3) 1 (1.7) ns 
LYPB/LYPB 1 (2.6) 1 (1.7) ns 
LYPB/HYPD 2 (5.1) 0 ns 
LYPA/HYPA 2 (5.1) 2 (3.4) ns 
HYPD/HYPA 0 2 (3.4) na 
Total 39 59 na 
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Table 7. MBL levels and gender 
 n 
Mean MBL levels (ng/mL) (±SD) 
p 
Male Female 
SLE 2 
1989.5 (2670.74) 
36 
2333.25 (2393.94) 
0.8 
Controls 4 
3107.5 (1157.39) 
55 
2517.35 (2537.66) 
0.65 
 
Table 8. MBL 2 genotype and mean MBL levels 
 Mean MBL levels (ng/mL)(±SD)  
MBL 2 
genotype 
SLE Control p 
YA/YA 4374.43 (2036.35) 4157.86 (2355.86) ns 
YA/XA 2636.71 (2249.57) 2855.65 (2511.58) ns 
XA/XA 1770 (636.4) 1676.6 (928.33) ns 
YA/O 711.67 (263.77) 661 (685.91) ns 
XA/O 30.6 (23.33) 98.5 (107.28) ns 
O/O 33 (45.27) 100  ns 
 
Table 9. Exon 1 MBL 2 polymorphisms and SLE clinical manifestations 
Clinical 
manifestations 
A/A 
  n (%) 
A/O and O/O 
n (%) 
p 
Cutaneous 10 (28.57) 16 (76.19) ns 
Arthritis 9 (25.71) 11 (52.38) ns 
Nephritis 6 (17.14) 5 (23.81) ns 
Serositis      2 (5.71) 12 (57.14) ns 
Neuropsychiatric 4 (11.43) 3 (14.29) ns 
Hematologic 4 (11.43) 9 (42.86) ns 
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Table 10. Characteristics of MASP-2 deficiency and non-deficient cases 
 
Table 11. MASP2 Asp105Gly genotypes and alleles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MASP-2 <200mg/mL 
n=33 
MASP-2>200ng/mL 
n=66 
p 
TB patient/HHC 18/15 31/55 ns 
HIV satus +/- 5/28 17/49 ns 
MBL deficiency (<500ng/mL) 4 (out of 32 patients) 15 (out of 61 patients) ns 
    
 Cases 
n (%) 
Controls 
n (%) 
p 
MASP 2 Allele 
A 78 (100) 103 (95.37) 0.14 
G 0 5 (4.63) na 
Genotype  
A/A 39 (100) 54 (91.53) 0.16 
A/G 0 5 (8.47) na 
G/G 0 0 na 
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14. Figures 
 
 
Figure 1: Influence of MBL2 genotype variants on serum MBL levels (ng/mL) in TB 
and HHC  
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Figure 2. Influence of MBL2 genotype variants on serum MBL levels (ng/mL) in SLE 
and healthy controls 
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Figure 3: Immunosupressive treatment in SLE patients 
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